Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Mining the Pipeline: Leading Investigational Products and Areas of Unmet Need

August 7th 2013

The oncology pipeline is crowded, despite the fact that the agents in development target a broad range of tumor types.

Ben Jones on Sequestration and Reimbursement

August 5th 2013

Ben Jones, Senior Director of Government Relations & Public Policy at McKesson Specialty Health & The US Oncology Network, discusses the impact of sequestration on drug and physician reimbursement.

Performance Metrics in Oncology

July 24th 2013

In 2011, the Medicare Electronic Health Record Incentive Program began paying physicians and hospitals for the measurement and reporting of performance metrics through the utilization of certified electronic medical record software.

Dr. Weber on Optimal Therapy Sequences in Melanoma

July 23rd 2013

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, discusses sequencing immunologic and targeted therapies in patients with advanced BRAF-mutated melanoma.

FDA Approves Afatinib for Metastatic NSCLC

July 12th 2013

The FDA has approved afatinib, along with a companion diagnostic, to treat patients with metastatic non-small cell lung cancer who express specific types of EGFR mutations.

Dr. Gogineni Comments on Oncology Drug Shortages

July 11th 2013

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Cost Versus Quality in Different Sites of Cancer Care

July 8th 2013

More oncology providers have shifted toward consolidation of practices to remain viable. In the last 4 years, 524 private practices have entered into agreements with or have been acquired by hospitals.

Priority Review Granted to Neoadjuvant Breast Cancer Regimen

July 2nd 2013

The FDA has granted priority review to a regimen of pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive early-stage breast cancer.

Conclusion: Key Take-Away Points and Cardiac Safety

July 1st 2013

Unmet Needs in Renal Cell Carcinoma

July 1st 2013

Immune Checkpoint Inhibition in Renal Cell Carcinoma

July 1st 2013

Novel Agents in Development for Renal Cell Carcinoma

July 1st 2013

INTORSECT Trial: Second-Line Temsirolimus Versus Sorafenib

July 1st 2013

Determining Progression in Renal Cell Carcinoma

July 1st 2013

AXIS Trial: Second-Line Axitinib Versus Sorafenib

July 1st 2013

Frontline Sunitinib Compared to Everolimus in mRCC

July 1st 2013

Utilizing Frontline Bevacizumab in mRCC

July 1st 2013

AGILE Trial: Frontline Axitinib Versus Sorafenib in mRCC

July 1st 2013

PISCES Trial and Patient Treatment Preference in mRCC

July 1st 2013

COMPARZ Trial and Alternate Sunitinib Dosing Schedule

July 1st 2013